Citi has increased its price target for Novo Nordisk to DKK330 ahead of the company's Q2 results, citing strong sales from the Wegovy pill launch. The broker raised its 2026 sales and operating income estimates by 4-5%, and earnings per share forecasts for 2027-2030 by about 7%, driven by currency effects and strong second-quarter trends for Wegovy. Despite some price pressure in obesity and diabetes treatments, the new oral Wegovy is expected to contribute significantly to revenue. Citi expects Novo Nordisk to possibly raise its full-year guidance due to strong prescription trends, but maintains a neutral rating as this upgrade is already priced in.
Novo Nordisk's shares have risen about 27% due to strong commercial growth of oral Wegovy, which holds 89% of new U.S. prescriptions compared to Eli Lilly's 11%. Over 80% of these prescriptions are from new GLP-1 patients, expanding the market rather...
Novo Nordisk initiated a share repurchase program starting February 2026, aiming to buy back up to DKK 15 billion of B shares within 12 months. As of July 17, 2026, the company has repurchased approximately 24.96 million B shares at an average price ...
Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insuli...
Novo Nordisk's stock has surged 40% since April, driven by the success of its oral Wegovy pill, which is expected to see significant revenue growth by Q2 2026 as it gains international approvals. This growth is notable especially as competitor Eli Li...
